HK1104795A1 - Dry formulations of aripiprazole - Google Patents

Dry formulations of aripiprazole

Info

Publication number
HK1104795A1
HK1104795A1 HK07113266.3A HK07113266A HK1104795A1 HK 1104795 A1 HK1104795 A1 HK 1104795A1 HK 07113266 A HK07113266 A HK 07113266A HK 1104795 A1 HK1104795 A1 HK 1104795A1
Authority
HK
Hong Kong
Prior art keywords
aripiprazole
dry formulations
tablets
compositions
dry compression
Prior art date
Application number
HK07113266.3A
Other languages
English (en)
Inventor
Julia Hrakovsky
Ruth Tenengauzer
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1104795(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1104795A1 publication Critical patent/HK1104795A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK07113266.3A 2006-01-05 2007-12-05 Dry formulations of aripiprazole HK1104795A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75670706P 2006-01-05 2006-01-05

Publications (1)

Publication Number Publication Date
HK1104795A1 true HK1104795A1 (en) 2008-01-25

Family

ID=36617397

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07113266.3A HK1104795A1 (en) 2006-01-05 2007-12-05 Dry formulations of aripiprazole

Country Status (14)

Country Link
US (2) US20070154545A1 (de)
EP (1) EP1808165B1 (de)
JP (1) JP2008531738A (de)
CN (1) CN101351193A (de)
AT (1) ATE429906T1 (de)
CA (1) CA2627695A1 (de)
DE (1) DE602006006536D1 (de)
DK (1) DK1808165T3 (de)
ES (1) ES2325219T3 (de)
HK (1) HK1104795A1 (de)
IL (1) IL190915A0 (de)
PL (1) PL1808165T3 (de)
PT (1) PT1808165E (de)
WO (1) WO2007081367A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200604349A2 (tr) * 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
WO2010079506A2 (en) * 2008-06-23 2010-07-15 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of aripiprazole
US20120214820A1 (en) 2009-09-15 2012-08-23 Ratiopharm Gmbh Orally disintegrating pharmaceutical dosage form containing aripiprazole
TR201000948A1 (tr) * 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
EP2645994B1 (de) * 2010-11-30 2017-11-01 WisTa Laboratories Ltd. Formulierungen enthaltend methylthioninium chlorid
CN102850268B (zh) 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
JP2016204260A (ja) * 2013-10-04 2016-12-08 日本曹達株式会社 錠剤の製造方法
EP3065700A1 (de) * 2013-11-07 2016-09-14 Synthon B.V. Im mund zerfallende pharmazeutische zusammensetzungen mit aripiprazol
CN106943405B (zh) * 2016-01-06 2021-04-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
WO2017204582A1 (en) * 2016-05-27 2017-11-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof inhibiting growth of cancer cells and a stabilizer having low melting point
CN108014343A (zh) * 2017-12-21 2018-05-11 孟斯琴 一种治疗乳腺癌的药物组合物及其制备方法
CN111213650A (zh) * 2020-02-25 2020-06-02 晋江市老君日化有限责任公司 一种蚊香的制备工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
JP2003238393A (ja) * 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
AU2003230192A1 (en) * 2003-03-21 2004-10-11 Hetero Drugs Limited Novel crystalline forms of aripiprazole
EP1618103A2 (de) * 2003-04-25 2006-01-25 Cadila Healthcare Ltd. Polymorphe von aripiprazol
ATE411797T2 (de) * 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
PT1613598E (pt) * 2003-12-16 2012-01-13 Teva Pharma Métodos para preparar formas cristalinas de aripiprazol
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
EP1812397A1 (de) * 2004-11-18 2007-08-01 Synthon B.V. Verfahren zur herstellung von kristallinem aripiprazol
CN101087760B (zh) * 2004-11-18 2011-09-28 斯索恩有限公司 结晶的阿立哌唑溶剂化物
EP1686117A1 (de) * 2005-01-27 2006-08-02 Sandoz AG Polymorph und Solvate von Aripiprazol
ES2526415T3 (es) * 2005-03-17 2015-01-12 Synthon B.V. Comprimidos farmacéuticos de aripiprazol cristalino de tipo II
US20060258672A1 (en) * 2005-05-13 2006-11-16 Joseph Barbosa Multicyclic compounds and methods of their use
US20070014864A1 (en) * 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
EP1919453A2 (de) * 2005-12-22 2008-05-14 Teva Pharmaceutical Industries Ltd Verfahren zur reduktion der teilchengrösse von aripiprazol
EP1880714A1 (de) * 2006-07-20 2008-01-23 Helm AG Amorphes Aripiprazol und Verfahren zu dessen Herstellung

Also Published As

Publication number Publication date
US20130344146A1 (en) 2013-12-26
CN101351193A (zh) 2009-01-21
US20070154545A1 (en) 2007-07-05
ES2325219T3 (es) 2009-08-28
EP1808165B1 (de) 2009-04-29
IL190915A0 (en) 2008-11-03
DK1808165T3 (da) 2009-08-03
EP1808165A1 (de) 2007-07-18
ATE429906T1 (de) 2009-05-15
PL1808165T3 (pl) 2009-09-30
WO2007081367A1 (en) 2007-07-19
JP2008531738A (ja) 2008-08-14
PT1808165E (pt) 2009-06-09
DE602006006536D1 (de) 2009-06-10
CA2627695A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
HK1104795A1 (en) Dry formulations of aripiprazole
WO2006124748A3 (en) Multicyclic compounds and methods of their use
IL190916A0 (en) Wet granulation pharmaceutical compositions of aripiprazole
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
WO2008121767A3 (en) Stitched polypeptides
UA97502C2 (ru) Кристаллическая твердая основа разагилина
WO2007124090A3 (en) Lyophilized therapeutic peptibody formulations
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
IL204844A (en) Coinolone analogues, pharmaceuticals containing them and their uses
WO2008057550A3 (en) Stabilization of vaccines by lyophilization
GB0513692D0 (en) Novel pharmaceutical compositions
TW200732296A (en) Novel compounds
GEP20094784B (en) Sustained release pharmaceutical formulations
IL193024A0 (en) Levetiracetam formulations and methods for their manufacture
IL185197A0 (en) Ophthalmological pharmaceutical compositions
WO2008054808A3 (en) Elvucitabine pharmaceutical compositions
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2006091836A8 (en) Formulations of ladostigil tartrate
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
TW200638932A (en) CCI-779 polymorph and use thereof
IL192824A (en) Peptide compounds, pharmaceuticals containing them and their use
WO2007138468A3 (en) Processes for the preparation of lansoprazole
WO2007071444A3 (en) Esomeprazole arginine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130314